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Abstract 
Background: Escherichia coli causes over one third of the bacteraemia cases in England each year, 
and the incidence of these infections is increasing. 
Aim: To determine the underlying risk factors associated with E. coli bacteraemia.   
Methods: A three month enhanced sentinel surveillance study involving 35 National Health Service 
hospitals was undertaken in the winter of 2012/13 to collect risk factor information and further 
details on the underlying source of infection to augment data already collected by the English 
national surveillance programme. Antimicrobial susceptibility results for E. coli isolated from blood 
and urine were also collected.  
Findings: A total of 1,731 cases of E. coli bacteraemia were included. The urogenital tract was the 
most commonly reported source of infection (51.2% of cases) with prior treatment for a urinary tract 
infection being the largest independent effect associated with this infection source.  Half of all 
patients had prior healthcare exposure in the month prior to the bacteraemia with antimicrobial 
therapy and urinary catheterisation being reported in one third and one fifth of these patients. Prior 
healthcare exposure was associated with a higher proportion of antibiotic non-susceptibility in the 
blood culture isolates (P=0.001). 
Conclusion: Analysis of risk factors suggests potential community and hospital-related interventions 
particularly better use of urinary catheters and improved antibiotic management of urinary tract 
infections. As part of the latter strategy, antibiotic resistance profiles need to be closely monitored 
to ensure treatment guidelines are up to date to limit inappropriate empiric therapy.  
 
Keywords: 
Urinary Tract Infection, Risk Factors, Healthcare Associated, Community 
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Introduction  
Voluntary surveillance identified  Escherichia coli as the leading cause of bacteraemia in England, 
with increasing incidence over time despite the overall incidence of bacteraemia being in decline
1
. In 
2015, 37,273 cases of E. coli bacteraemia were reported to the English mandatory surveillance 
programme
2
. Thirty-day all-cause mortality in England for this infection was recently estimated as 
18.2% (17.8-18.7%), equating to 5,220 deaths over a 12-month period
3
. Thus appropriately targeted 
interventions are required to reduce morbidity and mortality associated with E. coli bacteraemia. 
Whilst English mandatory surveillance of E. coli bacteraemia (initiated in 2011) allows better 
estimation of E. coli bacteraemia incidence than previously possible, detailed epidemiological 
information is needed to elucidate the reasons behind observed trends. 
Following a recommendation from the UK government’s Advisory Committee on 
Antimicrobial Resistance and Healthcare Associated Infection (ARHAI), a sentinel surveillance 
scheme was initiated  to augment existing mandatory surveillance.
4
 The sentinel programme aimed 
to gather more detailed risk factor information for patients in the hospital and community settings. 
Specific data collected included antibiotic consumption, use of urinary catheters, indwelling vascular 
access and other devices, and invasive procedures prior to the bacteraemia. Additionally we aimed 
to gather detailed information regarding the clinically identified focus or cause of bacteraemia and 
antibiotic susceptibility data for the E. coli blood and urine cultures.  
 
Methods 
Study design 
The sentinel study ran in participating English NHS Trusts (hospitals under the same 
management board) over the winter of 2012/13. The study was powered to detect with 95% 
confidence the prevalence of an underlying infection focus or risk factor with a true frequency of at 
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least 10%, based on estimates of the prevalence of the second commonest focus (hepatobiliary) 
reported via mandatory surveillance.
5
 As the sampling strategy was clustered (by NHS Trust and not 
patient) a design effect was included. This equated to a sample size of 2,625 E. coli bacteraemia 
cases; we therefore aimed to recruit 40 Trusts with data collection running over 3 months. 
Participating Trusts were selected using simple random sampling. Additionally, two specialist cancer 
Trusts and six interested Trusts were included post-hoc.  
Cases from the sentinel study were linked to mandatory E. coli bacteraemia reports (linked 
using NHS number, a unique personal identifier), to obtain further patient and specimen 
information, and to voluntary laboratory reports 
6
 (linked using a combination of available personal 
identifiers [NHS number, hospital number, date of birth, gender, encrypted surname]) to obtain 
antibiotic susceptibility data for both E. coli blood culture (if  not reported by sentinel sites) and 
urine cultures, one month and one year before the date of the blood culture. Duplicate entries for 
the same patient within the same episode (considered as 14 days), were removed from analysis with 
data relating to the earliest specimen retained. This study focused on E. coli bacteraemia and for 
cases of polymicrobial bacteraemia only information pertaining to the E. coli isolate was retained.    
Data items relating to healthcare exposure prior to the bacteraemia were collected. 
Specifically, in the prior three days: indwelling vascular access devices (in situ or removed), including 
the type of intravascular device; in the prior 7 days: urinary catheterisation (in situ, inserted, 
removed or manipulated), including the type of catheter, insertion method and primary indication 
for catheterisation; in the prior 4 weeks: other devices (in situ or removed), including the type of 
device and date of insertion; other procedures, including the type and date of procedure; and 
antimicrobial chemotherapy, including antibiotic name(s), indication and the treatment area. 
Patients with more than one healthcare exposure reported or more than one occurrence of a 
specific healthcare exposure were included in the study. Prior healthcare exposure in either the 
community or hospital in the 4 weeks and 1 week before bacteraemia was categorised as “Yes” if at 
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least one of the above data items were selected as “Yes” or as “No” if all of the above items were 
selected as “No”; otherwise it was coded as “Not known”.  In addition to these data items, the 
primary focus or reason for the bacteraemia was collected. More detail on data collection can be 
found in Supplementary Information 1.  
Time of bacteraemia onset based on the days between hospital admission and the taking of 
a positive blood culture was categorised as follows: on or day after admission (a proxy for 
community-onset infection); 2-6 days after admission (proxy for early healthcare-onset infection); 7 
days or more after admission (proxy for late healthcare-onset infection); from a non-admitted 
patient.  
Information on susceptibility of the E. coli blood culture and urine isolates to ciprofloxacin, 
trimethoprim, co-amoxiclav, third-generation cephalosporins (cefotaxime/ceftazidime), 
carbapenems (imipenem/meropenem), gentamicin, nitrofurantoin and piperacillin/tazobactam was 
ascertained using laboratory data reported via the national voluntary surveillance system. The 
presence of a urine culture in the linked laboratory dataset was taken as a proxy for urinary tract 
infection (UTI) in the month or year prior to the E. coli bacteraemia. Combined susceptibility for 
blood cultures, using the above antibiotics, was categorised as: “non-susceptible” if the blood 
culture was recorded as non-susceptible to at least one of the aforementioned antibiotics; and 
“susceptible” if the blood culture was recorded as susceptible to all of the aforementioned 
antibiotics.  
Statistical analysis 
General associations between two variables were examined using the Chi
2 
test. Multivariable logistic 
regression was used to estimate the independent effects of prior UTI, prior treatment of a urogenital 
tract infection and urinary catheterisation, on having a urogenital tract focus of bacteraemia, 
controlled for the effects of age, gender, (both of which were considered a priori confounders thus 
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automatically included in the model) treatment specialty and timing of bacteraemia onset. Only the 
presence of a UTI in the month prior to the bacteraemia was used in the model as it was considered 
more directly relevant than a UTI one year prior. A random effects term was used to control for 
clustering by reporting Trust.  Variables that were not significant in the final model were omitted, 
even if the crude odds ratios showed a significant effect. All data management and analyses were 
performed using Stata 13.0.
7
 
 
Results 
Thirty-five NHS acute Trusts submitted data to the sentinel programme, representing 1,731 cases of 
E. coli bacteraemia. Thirty-seven cases could not be linked to the mandatory surveillance dataset 
and were excluded from analysis and six cases were removed as within-episode duplicates. We 
achieved 90% power in our estimate of a risk factor or focus with a frequency of 10%. Distributions 
of cases from this sentinel study compared to the national mandatory data by patient sex or age and 
by time of onset or focus of bacteraemia were not statistically distinct P>0.05 (data not shown).  
Description of the study participants  
Half of the bacteraemias (n= 833; 49.3%) were in patients aged >75 years, and around half 
were in women (n=901; 53.4%) (Table 1). Over two-thirds of patients had a positive blood culture 
taken 0-1 day after admission (n=1,153; 68.3%).  The underlying infection focus was reported as the 
‘urogenital tract’ in 51.2% (n=865) of patients. The next most frequent foci were ‘hepatobiliary’ 
(15.6%; n=264), and ‘unknown’ (14.9%; n=252).  
Healthcare exposure prior to the bacteraemia  
Half (n=930) of the patients had a healthcare exposure, as defined in the Methods section, in 
the four weeks prior to the bacteraemia and one third (n=584) had a healthcare exposure in the 
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week prior to the bacteraemia.  The percentage of patients with prior healthcare exposure increased 
as the time of bacteraemia onset after hospital admission increased (Figure 1). Of the patients 
diagnosed 0-1 day after admission, 46.7% (n=538) had a healthcare exposure in the month prior to 
the bacteraemia, increasing to 85.4% (n=251) in patients in hospital for ≥7 days prior to the 
bacteraemia reflecting the increased opportunity of  healthcare exposure for admitted patients as 
well as potentially more comorbidities. Stratification by age showed some variation in prior 
healthcare exposure four weeks prior to the bacteraemia, with 26.9% (n=7) of 0-1 year olds, 54.3% 
(n=95) of 1-44 year olds, 57.5% (n=651) of 45-84 year olds and 49.9% (n=177) of patients 85 years or 
more having had a prior healthcare exposure (details not shown). 
Antimicrobial therapy was the most commonly reported prior healthcare exposure in one 
third (n=546) of patients (Table 1);-of these 546 patients 58.4% (n=319) received one antibiotic, 
23.1% (n=126) received two and the remaining 101 received three or more. Seventy-nine percent 
(721/907) of the antibiotic prescriptions were for treatment of infection. Treatment for infection of 
the urogenital tract was most commonly reported (n=229; 31.8%), followed by treatment of the 
respiratory tract (n=123; 17.1%).  For patients treated for urogenital tract infection, trimethoprim 
and co-amoxiclav were most commonly prescribed (n= 50 [21.8%] and n= 47 [20.5%], respectively). 
Fourteen percent (125/907) of prescriptions were for medical or surgical prophylaxis; where the site 
was reported (n=115), 26.1% (n=30) of prescriptions were for a genito-urinary site. Twelve of these 
patients were catheterised in the three days prior to the bacteraemia. It was not possible to 
determine if these patients were also treated for a UTI as treatment and prophylaxis were mutually 
exclusive options.   
Twenty-two percent of patients (n=373) had an indwelling intravascular device that either 
remained in situ at the onset of the bacteraemia, or had been removed within the 3 days prior to the 
bacteraemia (Table 1). Of these patients, 88.2% (n=329) had one indwelling intravascular device and 
8.0% (n=30) had two with the remainder having between three and six. Where reported (n=444), the 
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most common catheter types were peripheral (41.6%; n=184), and central venous catheters (11.8%; 
n=52).  
Twenty-one percent of patients (n=354) either had a urinary catheter in place at the time of 
the bacteraemia, or  had one inserted, removed or manipulated in the 7 days prior to the 
bacteraemia (Table 1); of these, 96.9% (n=343) were catheterised just once.  Where reported 
(92.7%; n=328) urinary retention (27.1%; n=89) and fluid balance (21.6%; n=71) were the primary 
reasons for catheterisation. Eleven percent (n=36) of patients had a catheter inserted for 
incontinence. The reason for catheterisation was unknown in 19.2% (n=63) of instances. The primary 
insertion type was urethral (91.8%; n=302). Long term (in situ ≥28 days) and short term (in situ <28 
days) catheters predominated (41.3%; n=152 and 38.3%; n=141, respectively), the remaining 20% 
were reported as temporary catheters. Among the patients whose bacteraemia was detected ≥7 
days after hospital admission (n=294) 40.1% (n=118) had been subject to urinary catheterisation in 
the 7 days before bacteraemia. The equivalent figure for patients with a bacteraemia detected 2-6 
days after admission was 36.4% (n=47/129) and for those detected on admission it was 15.4% 
(n=178/1,153).  
Twelve and seven percent (n=209 and n= 123, respectively) of patients had another 
procedure or device in the four weeks before bacteraemia. Of the available procedure categories, 
‘other’ was most frequently selected (64.3%), of which approximately half were surgical procedures.  
Patients with an underlying urinary focus of bacteraemia 
Six-hundred and ninety (79.8%) of the 865 patients where the underlying infection focus was 
reported as the ‘urogenital tract’ were recorded as having a UTI. Amongst those patients with a 
urogenital tract focus where the date of infection onset was recorded (n=510), 48.4% (n=248) had 
the blood culture taken on the day of onset, while for a further 214 patients (41.8%) the onset of 
infection occurred up to 7 days before the positive blood culture was taken.  Where the urogenital 
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infection was reported as catheter-, procedure-, or device-related (n=171), 84.2% (n=144) were 
related to a urinary catheter, 12.3% (n=21) to a procedure and the remainder (3.5%; n=6) to a 
device. Where information on prior UTIs was reported, two thirds of patients (62.4% n=176/282) 
had at least one prior UTI. Of patients with a urogenital tract focus with at least one antibiotic 
prescribed in the four weeks prior to bacteraemia, 51.6% (145/281) of antibiotics were prescribed 
for treatment of urogenital system-associated infection. Where reported co-amoxiclav (23.1%; 
n=29/212) and trimethoprim (22.2%; n=47) were most commonly prescribed, whilst 9.9% (n=21) 
were prescribed nitrofurantoin.  
 
Regression analysis of factors associated with urinary tract focus of infection 
 The largest independent risk factor for a bacteraemia’s underlying focus being  the 
urogenital tract was prior treatment for urogenital tract infection within 4 weeks of the bacteraemia 
onset: adjusted OR (aOR) 10.7 (95% confidence interval (CI): 6.3-18.1) (Table 2). Having had a UTI in 
the month prior to bacteraemia increased the odds of urogenital tract-related bacteraemia 5-fold 
(aOR 5.4; 95% CI 3.6-8.1). Having a catheter inserted for incontinence (versus ‘other’) and surgical 
specialty (versus medical specialty) also increased the odds of a urogenital tract focus (aOR 5.2; 95% 
CI: 1.5-18.1 and aOR 4.3; 95% CI 2.0-9.3, respectively). Several factors were associated with a 
reduction in the odds of a urogenital tract focus of infection including male gender, unknown 
presence of catheter, general specialty and bacteraemia detected 2-6 days or ≥7 days post 
admission.  
Antibiotic susceptibility 
Where tested, the highest levels of antibiotic non-susceptibility among isolates from blood 
were to co-amoxiclav (43.0% [n=511/1,188]) or trimethoprim (40.5% [n=317/783]) (Figure 2). 
Ciprofloxacin non-susceptibility was seen in 17% of tested isolates (n=187/1,100). Carbapenem non-
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susceptibility was only observed in two isolates out of 1,060 tested. There was an association 
between timing of bacteraemia onset and co-amoxiclav (p=0.027) and piperacillin/tazobactam 
(p=0.008) susceptibilities, both of which showed a greater proportion of non-susceptible isolates 
from patients with  bacteraemia detected 2 or more days after hospital admission (Table 3). 
Ciprofloxacin (p=0.02) and trimethoprim (p<0.001) non-susceptibility were associated with different 
foci of infection with a greater percentage of isolates non-susceptible to ciprofloxacin found in 
patients with “pneumonia” reported as the underlying infection focus (23.7%; 9/38), whilst 
trimethoprim non-susceptibility was most commonly observed in patients with an underlying 
urogenital tract focus (48.1%; 198/412) (Table 4).  There was an association between antibiotic non-
susceptibility of blood culture isolates and healthcare exposure in the four weeks prior to the 
bacteraemia (P=0.001), with 60.9% (n=406/667) of isolates from patients with prior healthcare 
exposure showing non-susceptibility to at least one of the antibiotics tested versus 50.7% 
(n=165/330) of isolates without a prior healthcare exposure (data not shown). Antibiotic non-
susceptibility was also associated with antibiotic exposure in the four weeks prior to bacteraemia 
(P<0.001), the rates of non-susceptibility being 66.5% (n=262/394) and 51.4% (n=244/475), in those 
with and without prior antibiotic exposure respectively (data not shown).      
Urine cultures with antibiotic susceptibilities one year and four weeks prior to the E. coli 
bacteraemia were identified for 340 (20.1%) and 230 (13.6%) patients, respectively. The highest 
levels of non-susceptibility in isolates from urine at both time points were for trimethoprim (47.7% 
[n=162/340] at one year and 46.3% [n=106/229] at four weeks (not shown). Co-amoxiclav non-
susceptibility was also common at around 30% at both time points. Ciprofloxacin non-susceptibility 
was seen in 20.4% (n=47/231) and 15.5% (n=23/148) of urinary isolates in the year and four weeks 
prior to the bacteraemia. The levels of non-susceptibility to third-generation cephalosporins at the 
same time points were 21.3% (29/136) and 13.8% (12/87), respectively. Non-susceptibility to 
piperacillin/tazobactam was 22.1% (28/127) at one year and 24.4% (20/82) at four weeks prior to 
the bacteraemia. Non-susceptibility to nitrofurantoin was low, being reported in 6.9% (22/321) of 
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isolates at one year and 4.6% (10/216) at one month.  Only one patient’s infection was caused by E. 
coli non-susceptible to carbapenems at both time points.  
Where antibiograms were available for both urine and blood isolates from the same patient, 
there was a significant association between non-susceptibility in urine and the subsequent blood 
culture for each of the antibiotics examined, the association being stronger for isolates taken up to 
four weeks prior to the bacteraemia compared with the association at one year (data not shown).    
 
Discussion  
While large declines in infections such as methicillin-resistant Staphylococcus aureus 
bacteraemia occurred concomitant with healthcare-based interventions (e.g. intravascular device-
related care bundles; screening/decolonisation of high risk patients), E. coli bacteraemia is 
frequently considered a community-associated infection with lesser scope for reducing incidence.
8
-
10
 
All potential areas for  reducing E. coli bacteraemia incidence do, however, need to be investigated 
given the high burden of this infection (37,273 cases reported for 2015
2
) as even small reductions in 
incidence could  equate to thousands of patients a year.  The data presented here highlight potential 
interventions for reducing E. coli bacteraemia incidence, such as improved urinary catheter care and 
UTI diagnosis and management.  
Several of our findings suggest treatment failure in UTIs is an important risk factor for the 
development of E. coli bacteraemia. Hence prompt diagnosis and appropriate treatment of UTIs, the 
commonest underling focus of E. coli bacteraemia identified here and elsewhere,
11,12 with 
antibiotics to which the organism is susceptible are key in limiting progression from UTI to 
bacteraemia and severe sepsis. Antibiotic therapy in the four weeks before bacteraemia was the 
most commonly reported healthcare exposure (one third of patients), and of these patients almost 
one third were prescribed antibiotics for treatment of a genito-urinary infection. Notably the most 
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commonly prescribed antibiotics for these patients were trimethoprim and co-amoxiclav, where 
non-susceptibility in urine isolates was common (around 47% and 30%).  Furthermore, trimethoprim 
non-susceptibility was common (40.5%) in E. coli blood isolates. This may reflect prior trimethoprim 
exposure in the treatment of the patient’s UTI with subsequent selection of resistant strains leading 
to treatment failure and progression to bacteraemia, or UTI caused by uropathogenic strains already 
resistant to trimethoprim. These findings are concerning in relation to trimethoprim as this antibiotic 
typically dominated  first-line treatment recommendations for uncomplicated UTI in primary care,
13
 
and thus is commonly prescribed,
14
 as supported by our findings. However it is reassuring that 
recent guidelines now advocate nitrofurantoin therapy with trimethoprim use dependant on local 
resistance patterns.
15
 This reiterates that guidelines for empiric UTI therapy need constant review 
and updating. Whilst nitrofurantoin non-susceptibility was lower at around 5-7%, trends need to be 
monitored given its increasing importance in empiric UTI therapy. Non-susceptibility to third-
generation cephalosporins in urine was higher than typically seen in E. coli blood isolates, especially 
in patients with a history of UTIs within a year  before bacteraemia; these  patients may represent 
UTI treatment failures or those carrying multi-drug resistant, but not especially virulent, isolates. 
Furthermore, the association between resistance in urine before bacteraemia is consistent with a 
recent meta-analysis showing that  prior antibiotic exposure increased the odds of antibiotic non-
susceptibility.
16
 Whilst ciprofloxacin, third-generation cephalosporins, gentamicin and carbapenems 
are less frequent first-line therapies for  UTIs,
14
 they are important for treating more severe 
infections, thus  non-susceptibility trends  should be monitored.  
Prior healthcare exposure, regardless of whether it was one week or month prior to the 
bacteraemia case, primarily equated to antibiotic prescribing and was perhaps an important factor 
for subsequent non-susceptible E. coli bacteraemia. This highlights patient groups with E. coli 
bacteraemia who may be more likely to have a non-susceptible infection and justifies the current 
focus on antibiotic prescribing and antimicrobial resistance. We noted a general trend for increased 
non-susceptibility with healthcare-onset bacteraemia cases; however this was only significant for co-
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amoxiclav and piperacillin/tazobactam. This is most likely due to these being common first-line 
therapy for patients presenting at hospital with an infection and where these infections 
subsequently progress to a bacteraemia resistant isolates will be selected for. A larger study may 
have also identified significant associations for other antibiotics.  
Regression analysis somewhat predictably identified prior urogenital tract infection 
treatment and having a UTI in the month prior to the bacteraemia as  the most important risk factors 
for the development of a (presumed) urogenital tract focus bacteraemia, increasing  the odds of a 
urogenital tract focus  10.7 and 5.4 fold, respectively. We hypothesise that patients with urine 
samples sent for antimicrobial testing would more likely have experienced treatment failure  or had 
a complicated UTI, as most uncomplicated UTIs are typically treated empirically in  primary care.
17
 
Furthermore, three quarters of patients with a urogenital tract focus had their bacteraemia detected 
on admission. This implies either a failure in diagnosis and treatment of UTI in the community or 
patients presenting directly to the hospital with bacteraemia who have not visited their primary care 
physician for treatment of their symptoms. Greater awareness of the patient groups at risk of UTIs 
developing into bacteraemia in the community and hospital could reduce treatment failure or 
unrecognised complicated UTIs progressing to bacteraemia, through for example enhanced 
monitoring of patients with suspected UTI and prompt intervention when empirical treatment fails. 
Mid-stream urine sampling of all patients with symptomatic UTI, or where otherwise indicated in the 
guidance for susceptibility screening would also allow appropriate antibiotic therapy to be 
prescribed. 
17
  Further studies are warranted to gain a better understanding of who these patients 
are and what the potential intervention opportunities may be. Near patient testing for antimicrobial 
resistance may be a future option to improve management. Furthermore reduction of UTI incidence 
would limit the largest underlying focus of E. coli bacteraemia; studies are required to understand 
how this can be achieved.   
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Urinary catheter use was also identified as an important risk factor. We found that 21% of 
patients had a urinary catheter inserted, removed or manipulated in the week before bacteraemia; 
144 reported bacteraemias were likely related to a urinary catheter in the study. Urinary catheters 
inserted for incontinence were associated with a 5.2-fold increase in the risk of a urinary focus of 
infection.  Whilst incontinence and the other main reasons for catheterisation (urinary retention and 
fluid balance) could be considered appropriate indications,
18
 without more detailed patient medical 
history  it is not possible to determine whether each catheter was appropriately used. Additionally, it 
is concerning that for one in five catheterised patients the indication for catheterisation was not 
known/recorded, indicating a lack of optimised patient management , possibly increasing the risk of 
complications. Furthermore, almost half of the catheterised patients had a long-term catheter. 
Although this may have been appropriately indicated, it nonetheless increases the risk of infection 
compared to short-term catheters as the risk of infection developing from catheters increases with 
catheterisation duration.
19
 Periodic review of patients with long term catheters is advised 
20
 and 
should be followed. Further research is required to determine if suprapubic versus urethral long 
term catheters would present a lower infection risk both of which may reduce urinary catheter-
related infections. 
There is considerable literature highlighting high levels of catheter use in healthcare,
14,21,22 
with evidence for a large proportion of such usage being inappropriate and/or poorly monitored.
23,24  
We identified that the percentage of patients with a urinary catheter increased from 15.4% in those 
diagnosed around admission to 40.1% in those diagnosed ≥ 7 days after admission. This identifies 
the importance of appropriate catheter care in the community as well as close monitoring in 
hospitalised patients. The latter represent a patient group where device-related hospital-based 
interventions could be targeted to reduce E. coli bacteraemia incidence, although it is worth noting 
that the present data is unable to identify which patients may be catheterised as part of the sepsis 
pathway for monitoring of urinary output. 
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Urinary catheter use is associated with an increased risk of complications, notably catheter-
associated UTI.
22,25,26 Given the urinary tract is the predominant underlying focus of E. coli 
bacteraemia, appropriate catheter use and management are obvious interventions, particularly 
when the catheter is used solely for incontinence where non-invasive treatment options exist. As 
with the management of UTIs, any such intervention must be targeted at the community and 
hospital setting as many catheterised patients reside in the former 
21
 supported by the data here.  
These sentinel data are representative of the national picture of E. coli bacteraemia, based 
on comparisons of age, gender, timing of bacteraemia onset and underlying focus of infection. 
Despite a smaller sample size than intended, the power of the sentinel study was 90% to detect a 
risk factor or focus with a frequency of 10%.  There are, however, several limitations to the present 
study. Our study has only collected information on patients with E.coli bacteraemia therefore it is 
not possible to compare the population with and without infection, nor to estimate the impact of 
interventions on reducing E.coli bacteraemia incidence. The susceptibility results relate to 
antimicrobials tested which were not necessarily those received by the patient. Thus, it is not 
possible to determine the effects of antimicrobial exposure for the treatment of UTI on subsequent 
non-susceptibility in blood cultures. Additionally antimicrobial testing practices vary by laboratory 
and some antibiotics are less frequently tested which may impact on the linked urine antimicrobial 
results. Robust information on the management and treatment of prior UTIs and catheter use would 
provide further resolution on specific risk factors.  
It is clear from this study that E. coli bacteraemia is often secondary to an earlier UTI. 
Therefore, prevention of UTIs, particularly in the elderly, may reduce bacteraemia developing.  We 
have highlighted potential interventions and further research  to reduce the incidence of E. coli 
bacteraemia in England: 1) close monitoring and effective treatment of patients with suspected UTI; 
2) awareness of local antibiotic resistance profiles with early recognition of UTI treatment failure 
with prompt initiation of effective antimicrobial therapy; 3) early identification of suspected 
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bacteraemia secondary to UTI, primarily in the community; 4) appropriate use and management of 
urinary catheters in the hospital and community with monitoring for signs of infection; 5) further 
research on UTI incidence in England, infection rates in suprapubic versus long term catheters, and 
antibiotic consumption patterns.  
Whilst interventions targeted at the community setting may be harder to implement and 
monitor than hospital-based interventions, this should not be a reason for not trying, given the high 
burden of E. coli bacteraemia.  
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Table 1.Description of the E. coli bacteraemia sentinel study participants 
Patient and specimen characteristics 
  N % 
    Total study participants 1,688   
Patient and 
specimen details 
  
  
  
  
  
Age group (years) 0-<1 26 1.5 
1-14 14 0.8 
15-44 161 9.5 
45-64 312 18.5 
65-74 342 20.3 
75-84 478 28.3 
  85+ 355 21.0 
Gender Female 901 53.4 
Male 753 44.6 
  Unknown 34 2.0 
Timing of E. coli bacteraemia onset 0-1 after admission 1,153 68.3 
2-6 days 129 7.6 
>=7 days 294 17.4 
Not admitted 110 6.5 
  Not reported 2 0.1 
Specialty Medical 1,162 68.8 
General 236 14.0 
Surgical 60 3.6 
Not known 59 3.5 
  Not reported 171 10.1 
Underlying focus of infection Bone and joint infection 7 0.4 
Central nervous system 1 0.1 
Contaminant 5 0.3 
Febrile neutropenia 54 3.2 
Gastrointestinal tract 118 7.0 
Hepatobiliary 264 15.6 
Indwelling intravascular device 19 1.1 
Other 29 1.7 
Pneumonia 54 3.2 
Skin/soft tissue infection 18 1.1 
Unknown 252 14.9 
Urogenital tract 865 51.2 
  Not reported 2 0.1 
Healthcare 
exposure 
  
  
  
  
  
  
  
Any exposure in the week prior to 
bacteraemia Yes 584 34.6 
No 949 56.2 
  Not known 155 9.2 
Any exposure in the month prior to 
bacteraemia Yes 930 55.1 
No 458 27.1 
  Not known 300 17.8 
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Antibiotics in the 4 weeks prior to the 
bacteraemia Yes 546 32.4 
No 681 40.3 
Not known 459 27.2 
  Not reported 2 0.1 
Urinary catheter in situ, inserted, removed, 
manipulated in the 7 days prior to the 
bacteraemia 
Yes 354 21.0 
No 1,206 71.5 
Not known 128 7.6 
Indwelling vascular access device in situ, 
or removed in the 3 days prior to the 
bacteraemia 
Yes 373 22.1 
No 1,190 70.5 
Not known 125 7.4 
Other devices in situ or removed in the 4 
weeks prior to the bacteraemia Yes 123 7.3 
No 1,332 78.9 
Not known 233 13.8 
Other procedures in the 4 weeks prior to 
the bacteraemia 
  
Yes 209 12.4 
No 1,213 71.9 
Not known 265 15.7 
Not reported 1 0.1 
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Table 2. Crude and adjusted1 odds ratios for risk factors for genito-urinary focus of E. coli 
bacteraemia 
Variable   Crude OR 
95% Confidence 
interval P value Adjusted OR 
95% confidence 
interval P value 
Gender Female 1   
Male 0.7 0.6 0.9 0.0018 0.7 0.5 0.9 0.001 
Age group (years) 1-44 1   
0<1 0.7 0.3 1.5 0.3201 1.2 0.5 2.9 0.748 
45-84 0.7 0.5 1.0 0.0603 0.8 0.6 1.2 0.358 
>=85 1.0 0.7 1.4 0.9594 1.0 0.6 1.5 0.948 
UTI in the month prior 
to bacteraemia None 1   
>=1 4.1 2.9 5.7 <0.001 5.4 3.6 8.1 <0.001 
    
Urinary catheterisation 
in the 7 days  prior to 
the bacteraemia 
No 1   
Yes 2.2 1.7 2.9 <0.001 1.8 0.9 3.8 0.108 
Not known 0.5 0.4 0.8 0.0015 0.4 0.3 0.7 0.001 
Duration of 
catheterisation No catheters 1   
Short term  1.6 1.1 2.2 0.0062 
Long term 5.0 3.2 7.7 <0.001 
Not known 1.3 0.7 2.3 0.4867 
Omitted due to collinearity  with “Urinary 
catheterisation in the 7 days  prior to the 
bacteraemia” 
Insertion method of 
urinary catheter No catheter 1   
Suprapubic 5.6 1.2 25.8 0.0123 
Urethral 2.6 2.0 3.4 <0.001 
Don't know 1.1 0.4 3.2 0.8282 Not included 
Reason for urinary 
catheterisation Not reported 1   
Other 2.0 1.5 2.7 <0.001 2.0 0.9 4.4 0.09 
Incontinence 7.0 2.7 18.2 <0.001 5.2 1.5 18.1 0.009 
Not known 3.9 2.1 7.2 <0.001 2.6 1.0 7.1 0.061 
Treatment for a UTI in 
the month prior to the 
E. coli bacteraemia 
No 1   
Yes 7.7 4.7 12.5 <0.001 10.7 6.3 18.1 <0.001 
Specialty  Medical 1   
General 0.5 0.4 0.7 <0.001 0.6 0.4 0.9 0.016 
Surgical 4.1 2.1 8.0 <0.001 4.3 2.0 9.3 <0.001 
Not known 1.3 0.8 2.3 0.2821 1.8 0.9 3.4 0.074 
Not reported 1.0 0.7 1.4 0.9066 1.2 0.7 1.9 0.578 
Timing of E. coli 
bacteraemia onset 
0-1 day after 
admission 1   
2-6 days 0.6 0.4 0.8 0.0023 0.4 0.2 0.6 <0.001 
>=7 days 0.5 0.4 0.6 <0.001 0.3 0.2 0.4 <0.001 
not admitted 0.8 0.6 1.3 0.4059 1.0 0.6 1.8 0.987 
Not reported 0.8 0.0 12.6 0.8658 0.5 0.0 9.6 0.639 
1. Final model includes risk factors identified from the literature and age and gender as a priori risk factors. Other variables were only included if 
they changed the effect of the main risk factors and were associated in the crude analysis. Adjusted ORs are adjusted for all other risk factors in 
the final model. 
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Table 3.Antibiotic susceptibilities of the E.coli blood culture by timing of bacteraemia onset in 
relation to hospital admission 
 
    Timing of E. coli bacteraemia onset in relation to hospital admission   
  
0-1 day after 
admission 2-6 days >=7 days Not admitted 
Antibiotic name 
Susceptibility 
result N % N % N % N % P-value 
Ciprofloxacin NS 124 16.6 13 16.9 36 19.7 14 15.4 
S 623 83.4 64 83.1 147 80.3 77 84.6 
  Total 747 100 77 100 183 100 91 100 0.758 
Trimethoprim NS 210 40.3 22 40.0 55 45.1 28 33.7 
S 311 59.7 33 60.0 67 54.9 55 66.3 
  Total 521 100 55 100 122 100 83 100 0.449 
Co-amoxiclav NS 326 40.5 48 54.6 96 48.2 41 44.1 
S 480 59.6 40 45.5 103 51.8 52 55.9 
  Total 806 100 88 100 199 100 93 100 0.027 
Third generation 
cephalosporins NS 59 8.8 9 12.3 21 12.7 6 7.2 
S 614 91.2 64 87.7 144 87.3 77 92.8 
  Total 673 100 73 100 165 100 83 100 0.311 
Carbapenems NS 1 0.1 0 0 1 0.5 0 0 
S 706 99.9 80 100 183 99.5 88 100 
  Total 707 100 80 100 184 100 88 100 0.653 
Gentamicin NS 74 9.0 5 5.6 26 12.8 5 5.4 
S 746 91.0 84 94.4 178 87.3 88 94.6 
  Total 820 100 89 100 204 100 93 100 0.105 
Piperacillin/tazobactam NS 77 9.9 15 18.1 34 17.3 13 14.1 
S 704 90.1 68 81.9 163 82.7 79 85.9 
  Total 781 100 83 100 197 100 92 100 0.008 
Nitrofurantoin NS 5 4.6 0 0 0 0 0 0 
S 103 95.4 9 100 22 100 5 100 
  Total 108 100 9 100 22 100 5 100 0.631 
S, susceptible; NS, non-susceptible 
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Table 4. Antibiotic susceptibilities of the E.coli blood culture by underling focus of the E. coli 
bacteraemia 
 
    Underlying focus of the E. coli bacteraemia   
  
Urogenital tract 
  
Pneumonia Other 
  
Not known 
  
Antibiotic name 
Susceptibility 
result N % N % N % N % P-value 
Ciprofloxacin NS 108 18.5 9 23.7 55 17.6 15 9.0 
S 475 81.5 29 76.3 257 82.4 152 91.0 
  Total 583 100 38 100 312 100 167 100 0.02 
Trimethoprim NS 198 48.1 3 13.6 79 38.0 37 26.2 
S 214 51.9 19 86.4 129 62.0 104 73.8 
  Total 412 100 22 100 208 100 141 100 <0.001 
Co-amoxiclav NS 283 45.4 14 35.9 145 43.8 69 35.6 
S 340 54.6 25 64.1 186 56.2 125 64.4 
  Total 623 100 39 100 331 100 194 100 0.08 
Cephalosporins NS 55 10.8 2 6.7 25 9.0 13 7.4 
S 455 89.2 28 93.3 254 91.0 163 92.6 
  Total 510 100 30 100 279 100 176 100 0.521 
Carbapenems NS 1 0.2 0 0 1 0.3 0 0 
S 542 99.8 38 100 304 99.7 174 100 
  Total 543 100 38 100 305 100 174 100 0.87 
Gentamicin NS 62 9.8 3 7.7 36 10.5 9 4.6 
S 569 90.2 36 92.3 306 89.5 186 95.4 
  Total 631 100 39 100 342 100 195 100 0.108 
Piperacillin/tazobactam NS 83 14.0 5 13.2 37 11.3 14 7.3 
S 512 86.1 33 86.8 292 88.8 178 92.7 
  Total 595 100 38 100 329 100 192 100 0.095 
Nitrofurantoin NS 2 2.2 0 0 3 8.3 0 0 
S 89 97.8 2 100 33 91.7 15 100 
  Total 91 100 2 100 36 100 15 100 0.309 
S, susceptible; NS, non-susceptible 
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Figure 1. Timing of E. coli bacteraemia onset and history of healthcare interaction in the month prior 
to the bacteraemia 
 
 
Excludes 2 patients where admission status could not be ascertained 
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Figure 2. Antibiotic susceptibilities of the E.coli blood culture 
 
 
Numbers in parentheses indicate the total number of isolates tested 
